Updated:
FemHealth Ventures
FemHealth Ventures is an SEC-registered investment adviser, established in 2023. It provides investment advice to clients.
FemHealth Ventures
FemHealth Ventures is an SEC-registered investment adviser, established in 2023. It provides investment advice to clients. The firm is registered with the SEC.
General information
Firm type
Venture Capital
Year founded
—
AUM
Undisclosed
Location
Region
North America
Country
United States
City
New York
Corporate office
New York, NY, United States
Principals
Maneesha Ghiya
Managing Partner
Sara Crown Star
Venture Partner
Stephanie Wang
Investor
Sector focus
Frequently asked questions
What is the FemHealth Framework, and why does it matter for deal sourcing?
Published by the firm in 2019, the FemHealth Framework sorts women's health conditions into three buckets: those appearing only in women, mostly in women, or differently in women. It functions as a proprietary sourcing screen, ensuring that portfolio companies address diseases where XX-chromosomal biology alters the clinical presentation or market need. The framework has been broadly adopted across the women's health investment ecosystem.
Which women's health categories does the firm explicitly invest in?
The firm invests across conditions that are only in women — such as endometriosis and cervical cancer — mostly in women, including breast cancer and lupus, and differently in women, like heart disease and diabetes. Its portfolio reflects this, holding companies in medical devices, therapeutics, diagnostics, and biobanking, all filtered through this lens.
Who leads investment decisions at FemHealth Ventures?
Managing Partner Maneesha Ghiya leads the firm, supported by Venture Partner Sara Crown Star and Investor Stephanie Wang. Ghiya and Crown Star share a 30-year professional relationship. The firm also relies on an advisory board that includes biotech CEOs, surgeons, and faculty from Harvard Business School and Wharton.
Is FemHealth Ventures structured as a traditional venture firm or does it have a single-family-office backing?
FemHealth Ventures operates as a dedicated venture capital firm, not a family office or corporate venture arm. No underlying single-family wealth source is disclosed publicly. Its structure is a standard asset manager raising external LP capital to deploy into early-stage women's health companies.
What is the firm's known posture on co-investments or syndication alongside other VCs?
The firm has not publicly detailed its syndication or co-investment practices. Published materials emphasize its proprietary sourcing lens rather than preferred deal structures, leaving its approach to leading versus following rounds unspecified.
What is the scale of the firm's deployment to date, and has it closed a formal fund?
No AUM or total deployment figure is publicly disclosed by the firm. It lists a portfolio of 21 named companies on its website, implying meaningful capital at work, but it has issued no press release confirming a fund size or close date.
Does FemHealth Ventures back men's health or general life-science companies, or is it exclusively women's health?
All disclosed portfolio companies target conditions that fit within the firm's three-category women's health framework. The firm's own marketing and framework explicitly center on conditions where female biology creates a distinct medical need, suggesting no generalist life-science or men's-health mandates operate alongside it.
Profile maintained by Altss using OSINT (open-source intelligence), regulatory filings, licensed data partners, and verified direct submissions. Read the methodology. Last updated: . Continuous refresh with full update cycles at least every 30 days.
Need institutional-grade insight on venture capital firms?
Altss delivers:
Prefer a guided tour?
We’ll walk you through: